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Abstract 
Rare copy number variants contribute significantly to the risk for schizophrenia, with the 
22q11.2 locus consistently implicated. Individuals with the 22q11.2 deletion syndrome 
(22q11DS) have an estimated 25-fold increased risk for schizophrenia spectrum disorders,
compared to individuals in the general population. The International 22q11DS Brain Behavior 
Consortium is examining this highly informative neurogenetic syndrome phenotypically and 
genomically. Here we detail the procedures of the effort to characterize the neuropsychiatric and 
neurobehavioral phenotypes associated with 22q11DS, focusing on schizophrenia and 
subthreshold expression of psychosis. The genomic approach includes a combination of whole 
genome sequencing and genome-wide microarray technologies, allowing the investigation of all 
possible DNA variation and gene pathways influencing the schizophrenia-relevant phenotypic 
expression. A phenotypically rich data set provides a psychiatrically well-characterized sample 
of unprecedented size (n=1,616) that informs the neurobehavioral developmental course of 
22q11DS. This combined set of phenotypic and genomic data will enable hypothesis testing to 
elucidate the mechanisms underlying the pathogenesis of schizophrenia spectrum disorders.
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INTRODUCTION
Advances in technology for the characterization of entire genomes, e.g. next generation whole 
genome sequencing (WGS), and the availability of large samples with DNA, promise to propel
our mechanistic understanding of neuropsychiatric disorders. Rare structural and other variants,
including copy number variants (CNVs), have contributed to recent advances. Large rare CNVs 
throughout the genome have been identified as contributors to the etiology of schizophrenia,
conferring significant risk with large effect sizes.
1-4
 Arguably, none is more clinically relevant or 
feasible as a model for focused investigation than the recurrent 22q11.2 deletion underlying the 
22q11.2 deletion syndrome (22q11DS).
4
The link between 22q11DS and schizophrenia has long been recognized.
5-11
Multiple 
studies confirm that ~1 in 4 individuals with 22q11DS develop schizophrenia, and that ~1 in 
100-200 individuals with schizophrenia in community samples have a 22q11.2 deletion.
12,13
These observations led a large international group of investigators to collaborate with the goal of
identifying the underlying mechanisms of schizophrenia expression in 22q11DS that may be 
applicable to idiopathic schizophrenia in the general population. They agreed to share phenotypic 
information and existing DNA samples. Recognizing the potential of this collaboration to 
provide a wealth of data on the link between 22q11DS and schizophrenia spectrum disorders, the 
U.S. National Institute of Mental Health (NIMH) has forged a collaborative effort to investigate 
this important neurogenetic syndrome through the newly established International 22q11DS
Brain Behavior Consortium (IBBC). Here we provide the goals and underlying hypotheses of the 
IBBC, an overview of clinical aspects of 22q11DS, and the rationale for focusing on this 
condition. We outline the phenotypic procedures and the genetics workflow, and summarize 
early findings.
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GOAL OF THE CONSORTIUM
The IBBC is taking a multifaceted unbiased genome-wide approach to uncover genetic variation
that contributes to the expression and high prevalence of schizophrenia in 22q11DS. The 
overarching hypothesis is that taking advantage of the magnifying effect of the 22q11.2 deletion 
and comprehensively studying genetic variation across the genome may elucidate genes and, 
more plausibly, gene networks and functional biological pathways that contribute to the etiology 
of schizophrenia and other neuropsychiatric phenotypes in 22q11DS and in the general 
population. A related hypothesis is that the study of youths with 22q11DS allows for the 
identification of early behavioral and/or cognitive markers associated with schizophrenia but 
preceding the onset of the first psychotic episode. It is expected that youths with 22q11DS and 
greater cognitive decline will share some of the genetic factors identified in individuals with
schizophrenia. The expectations are that the biological pathways identified may be similar to 
those for individuals with schizophrenia without the 22q11.2 deletion, and that the elevated risk 
in 22q11DS will provide an enhanced effect size to identify the salient genetic factors and 
systems involved.
14-16
THE 22q11.2 DELETION SYNDROME
The 22q11.2 deletion is the most common chromosomal microdeletion (~1:4000 live births; 
~1/1000 fetuses) associated with a highly penetrant genomic syndrome.
13
Over 90% of affected 
individuals have a ~3 million base pair (Mb) hemizygous deletion encompassing 46 protein-
coding and 44 additional genes (Figure 1).
13,17,18
Some have smaller nested deletions within the 
interval.
13
The deletion typically occurs as a de novo event arising by non-allelic homologous 
recombination between chromosomes during meiosis, mediated by chromosome-specific low-
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copy repeats across the chromosome 22q11.2 region.
19-21
The phenotypic presentation is heterogeneous, often involving multiple systems including
cardiac, palatal, endocrine, immune, gastrointestinal, skeletal and, most commonly,
neuropsychiatric abnormalities.
13
Brain dysfunction may be expressed as developmental delay 
and/or elevated prevalence of developmental neuropsychiatric disorders including attention 
deficit hyperactivity (ADHD), autism spectrum, anxiety and psychotic disorders.
22-26
 The ~25-
fold increased risk for psychotic illness in 22q11DS is far greater than the estimated 3-fold 
increased risk of psychotic illness associated with general developmental delay.
6,27
Therefore, 
22q11DS provides a unique opportunity to investigate mechanisms underlying the evolution of 
schizophrenia and schizophrenia spectrum features across the lifespan. The existence of mouse 
models of individual or multiple genes within the region of synteny to the human 22q11.2 region
also lays the foundation for a broad array of translational research to understand molecular 
mechanisms.
17,18, 28-32
The fact that the genetic risk is identifiable prenatally and postnatally,
13
coupled with 
comparable age at onset, symptom pattern and early clinical signs, including neurocognitive 
deficits, all similar to idiopathic disease, support 22q11DS as a particularly promising genetic 
model for schizophrenia.
14
SCHIZOPHRENIA SPECTRUM AND BRAIN BEHAVIOR PARAMETERS IN 22q11DS
As in the general population, schizophrenia in 22q11DS commonly emerges in late adolescence 
to early adulthood and is characterized by positive symptoms (hallucinations, delusions), 
negative symptoms (amotivation, asociality) and disorganized behavior.
33-35
 Within the context 
of the syndrome, response to antipsychotic medications appears similar to that in schizophrenia 
in the general population, considering the context of a multisystem disorder.
36, 37 
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Youths at risk for psychosis in the general population have been studied in help-
seekers
38,39
and community samples.
40,41
 Neurocognitive measures and neuroimaging parameters 
show abnormalities in at-risk individuals, suggesting the presence of neurobiological aberrations
early in the psychosis process.
42-44
 With a known high risk for schizophrenia, 22q11DS provides 
the opportunity to systematically investigate early abnormalities in development as well as the 
emergence of psychotic illness in cross-sectional and prospective studies of individuals who 
share the same genetic abnormality.
45-47
 Investigations applying standard procedures to assess 
subthreshold psychotic symptoms in 22q11DS have reported their presence across samples.
48-50
Integration of phenotypic parameters with genomics may generate mechanistic insights that lead 
to improved clinical diagnosis and offer new therapies.
Neurocognitive dysfunction is a central feature of schizophrenia
51
 with intellectual 
decline evident years prior to the emergence of psychotic symptoms.
52,53
Similarly, in 22q11DS 
there is a steeper decline in verbal IQ associated with the emergence of psychotic disorders.
46,54
Divergence of intellectual trajectories between those who subsequently develop a psychotic 
disorder and those who do not is distinguishable from age 11 years onward.
54
In schizophrenia, there are well-documented deficits in specific domains including verbal 
memory, executive functions and social cognition.
51,55
Comparable patterns of impairments 
evident in clinical high-risk populations,
56,57
and family members of patients,
58,59
implicate these 
as potential endophenotypes. Similar impairments in executive function, social cognition, non-
verbal memory, working memory and visual-spatial function in 22q11DS,
24,45-47,60-62
 suggest
possible sharing of underlying neural networks. 
Historically, studies of brain and behavior in 22q11DS have involved relatively small 
samples, with convergent findings emerging. Recognizing that multicenter samples are necessary 
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to generate large datasets, enabling integration of genomic and phenotypic data, investigators 
with complementary expertise who had established an international collaborative effort to study
22q11DS came together to form the IBBC.
THE INTERNATIONAL 22q11.2 BRAIN BEHAVIOR CONSORTIUM (IBBC)
OBJECTIVES
The IBBC established several aims to harmonize existing cohorts of 22q11DS participants with 
both phenotypic data and DNA available to perform next-generation sequencing and other 
genome-wide genomic analyses: 1) to examine the neuropsychiatric and neurocognitive-
behavioral phenotypes associated with schizophrenia spectrum disorders in 22q11DS; 2) to 
generate and analyze genome-wide data for >300 adults with 22q11DS, about half with 
schizophrenia and half, aged 25 years and older with no psychotic illness, and use the same 
strategy for at-risk youths with 22q11DS; 3) to develop and pilot commonly used measures to 
optimize assessment of neuropsychiatric and cognitive-behavioral phenotypes in 22q11DS as a 
platform for future prospective longitudinal studies; 4) to build coordinated resources in the 
public domain for the international scientific community. The genetic analyses involve genome-
wide data from WGS and high-resolution microarrays, with the goal of identifying genetic 
pathways that may influence the expression of schizophrenia and related phenotypes.
ORGANIZATIONAL STRUCTURE
The IBBC includes multiple international phenotyping sites, contributing DNA samples and 
phenotypic data, and genomic sites (Table 1). The phenotyping working group provides 
neuropsychiatric and neurobehavioral expertise and the genomic working group the genetic 
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analytic approach. An executive committee (EC) is comprised of 13 representatives from the 
working groups, including 9 members who lead the four phenotyping groups. The EC
communicates regularly by conference calls and in-person meetings to implement research plans,
communicate with NIMH, disseminate information to collaborative sites, arrange general 
meetings, oversee the development and quality of the database and the website, and review
proposals for ancillary studies and publications.
SAMPLE AND ELIGIBILITY CRITERIA
For inclusion in the study, the IBBC took advantage of available cohorts of well-characterized
individuals with 22q11DS where DNA samples exist. Initial steps in the IBBC study involve 
extensive quality control. These include reviewing the phenotypic data, verifying the presence of
a typical 22q11.2 deletion (Figure 1), and determining relatedness between and ancestry of 
participants with high-quality DNA samples. Table 2 details the sample characteristics.
PHENOTYPIC PROCEDURES
Psychiatric Assessment
Harmonization of existing clinical psychiatric data for the IBBC has involved two main phases. 
To enable dichotomous case-control categorization, the presence of schizophrenia (or related 
psychotic illness), or the absence of any psychotic illness in subjects assessed at age 25 years or 
older, is established for all subjects. Complementary methods enable the study of at-risk youths 
with 22q11DS. 
Schizophrenia spectrum disorders. Across sites, a semi-structured diagnostic 
interview,
63,64
with collateral information and medical records, provided details on clinical 
presentation and longitudinal history for establishing a DSM-IV diagnosis of schizophrenia, 
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schizoaffective disorder, or related psychotic disorders such as delusional disorder or psychotic 
disorder not otherwise specified. After extensive discussion, the few cases with a psychotic 
mood disorder were excluded from initial analyses. For phenotypic harmonization, two 
investigators with clinical expertise independently reviewed standardized clinical summaries 
(average 2-3 subjects/site). There was full consensus among the two reviewers and the diagnosis 
provided by the sites for case-control classification. Individuals of any age who met diagnostic 
criteria for a major psychotic disorder, predominantly schizophrenia, were included as cases. 
Non-psychotic adults. Participants > 25 years-old at the time of assessment, with no 
evidence for a psychotic disorder or psychotic mood disorder (i.e., bipolar disorder or major 
depression with psychosis), were classified as non-psychotic, as they were likely to be through 
the major risk period for developing psychosis. Consequently, individuals <25 years at the time 
of the last assessment without a psychotic disorder nor subthreshold psychotic symptoms are 
labeled as putative controls. This categorization does not exclude the possibility of other 
neuropsychiatric conditions that are common in 22q11DS (e.g., anxiety, ADHD).
22
Subthreshold psychosis youths. The majority of existing participants in the IBBC cohort 
are young, thus not yet through the risk period for developing schizophrenia when assessed 
(Table 2). Subthreshold psychosis is systematically assessed by applying established diagnostic 
interviews and scales.
65-67
 Investigators with expertise in child and adolescent psychiatry reached
a best estimate subthreshold psychosis designation based on review of a standard clinical 
summary provided across sites (on average 3 subjects/site). Subthreshold psychosis is applied 
when positive psychotic symptoms are persistently reported, but severity and impact on function 
do not justify a formal diagnosis of a psychotic disorder. Most sites provided quantification of
subthreshold symptom severity, based on structured interview data (Structured Interview for 
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Prodromal Syndromes, SIPS;
66
 or Comprehensive Assessment of At-Risk Mental States, 
CAARMS
67
). Because many youths who have not yet passed through the risk period for the 
development of psychotic illness have been followed longitudinally at IBBC sites, data available 
on quantitative cognitive phenotypes relevant to schizophrenia risk, including decline in verbal 
abilities in individuals,
54
 will also be used for genomic analyses. 
Cognitive assessments
Standardized IQ scores, available for many subjects across sites, provide measures of general 
cognitive ability, verbal abilities, nonverbal abilities, and selected executive functions. Using
both cross-sectionally and longitudinally obtained standardized IQ scores allowed definition of
an average cognitive trajectory for 22q11DS individuals, on which individual trajectories can be 
plotted to identify deviations from what is expected in this population. This approach has 
enabled generation of a quantitative measure of IQ decline as a phenotype of interest for genetic 
analyses.
46,54
To enhance commonality across other neurocognitive variables, several 
considerations were applied: representation across at least five IBBC sites, and comparability of 
neurocognitive test versions, administration procedures, and scoring. This will allow the 
application of standard procedures to create composite measures for the domains of executive 
function, social cognition and verbal learning. These domains were initially prioritized given 
their relevance of these domains to schizophrenia vulnerability.
51,56-59
 Also, the majority of sites 
used comparable measures within these domains.
GENOMIC APPROACH
The IBBC genomic approach to identify variants that may contribute to expression of 
schizophrenia and related conditions in the 22q11DS population is outlined in Figure 2. The 
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approach envisions testing four genetic models. One model is that variants on the haploid (single 
copy) 22q11.2 deletion region segment are enriched in those with psychotic illness and related 
conditions. The other three models will test for enrichment of genome-wide variants outside this 
22q11.2 region: in common sequence variants (i.e., single nucleotide polymorphisms (SNPs), in 
a traditional genome-wide association study (GWAS) paradigm), in rare sequence variants, and 
in rare structural variants. 
To test these models the IBBC plans to use both existing and new genotypic data. Indeed, 
a major focus of the IBBC is to generate WGS data for this valuable cohort. In comparison to 
whole exome sequencing, WGS permits more complete analysis of sequence and structural 
variation including coding and non-coding regions of the genome, while not suffering from 
capture and coverage biases.
67
 The rapid drop in price increased feasibility, and thus the bulk of 
the grant funding has supported the generation of WGS data for >80% of subjects in the IBBC 
22q11DS cohort (estimated n=1,576, before quality control measures, Figure 2). DNA samples 
were submitted for WGS (average depth 30X) using two platforms: for the first ~100 samples 
the Illumina HiSeq 2000,
68
 and thereafter the Illumina HiSeq X Ten. Initially, participants with 
schizophrenia (cases), or with no psychotic disorder and age ³25 years (controls), were 
prioritized.
Mapping and variant calling of SNVs (including SNPs) includes use of novel software 
tools (PEMapper/PECaller) developed at Emory.
69
 Cleaned and annotated (reference genome 
assembly GRCh38) sequence data are placed into Variant Call Format (VCF) and annotated 
using ANNOVAR,
70
enabling standard analytic approaches to be applied, including variant 
classes (i.e., exonic, intronic), rarity, and functional effects.
71-73
 Annotation of SNVs from coding 
regions uses standard pipelines and bioinformatic filters for functional impact.
15,74-78
 Similarly, 
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variants from non-coding regions are annotated using the most up-to-date methods available in 
this evolving area of genomic study.
15,74
WGS data allow detection of small structural variants beyond the resolution of 
microarray data. Calling of structural variants across the size spectrum from WGS data requires a 
combination of complementary methods. The analytic strategy for the IBBC includes 
interrogating read depth data, and discordant pair/split read data needed to call both balanced 
(inversions and translocations) and unbalanced (CNV) variants.
79-82
 CNV calls will provide a 
comprehensive genome-wide structural map for each subject, ready for further computational 
analyses. 
Complementing the WGS approach, the study takes advantage of existing data from 
Affymetrix 6.0 microarrays (Figure 2) available for many participating 22q11DS subjects from 
previous studies of cardiac phenotypes,
83,84
 with comparable array data generated for remaining 
subjects. Arrays provide both SNP data for use in genome-wide association study (GWAS) 
analyses and calculation of schizophrenia polygenic scores,
85
 and for genome-wide studies of 
structural variants (CNV) in addition to the 22q11.2 deletion.
86,87 
These common sequence and 
rare and common structural variant data also serve an important role in quality control, e.g., for 
comparison with variants identified by WGS.
The potential power of the proposed IBBC genomic approach and the enhanced effect 
sizes in 22q11DS are supported by the results to date reported in the Early Findings section 
below for additional rare structural variants.
87
 For genome-wide rare sequence variants, 
published power calculations in a proof-of-principle study using a WGS method to assess 
patients with 22q11DS with and without schizophrenia are available for gene-set burden 
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tests.
15
For n=100 subjects per group, power for plausible functional gene-sets was >0.90 for 
various types of coding sequence variants, with Cohens d effect size estimates of, e.g., 1.90, 
0.88, and 0.55, based on the nine genomes investigated.
15
With respect to aggregate common 
variants, there were also promising though non-significant results reported for the schizophrenia 
polygenic risk score in this study.
15
Estimates for detecting individual common variants with 
relative risk of 2 to 3 using a typical GWAS genome-wide significance threshold (5 x 10
-8
) show 
power >0.80 in the IBBC cohort (sample sizes as in Table 2) but, as expected, very low power 
for individual rare variants.
Variants in the 22q11.2 deletion region that increase likelihood of expressing schizophrenia 
and related phenotypes
Individuals with 22q11DS have just a single copy of the genes within the 22q11.2 deletion
region, a region of the genome well known for its complexity, partly due to the multiple low 
copy repeats (LCR22s) flanking and within this region (Figure 1).
19-21 
Comprehensive analysis of 
genotype-phenotype associations in 22q11DS mandates special expertise and consideration of 
this region. The IBBC study thus involves initial analysis of the haploid allele on the intact 
chromosome 22 separately from WGS data from the rest of the genome (Figure 2).
88,89
To call 
hemizygous single nucleotide variants (SNVs), PEcaller is rerun for this region in a haploid 
mode. 22q11.2 deletion region variants are then annotated and analyzed as for variants from 
other regions, but with special consideration of the hemizygosity and its potential effects on 
phenotype.
13
Detailed annotation and investigation of the complex architecture of the LCR22s,
89-
91 
and analysis of breakpoints and corresponding 22q11.2 deletion extent, including for rare 
nested 22q11.2 deletions, provide further unique data. These will allow regional and haplotype-
based analyses of the deleted or non-deleted allele, effects related to coding and non-coding 
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sequence variants within and flanking the 22q11.2 deletion region, and the potential for 
identifying hotspots for meiotic chromosomal rearrangements. Collectively, these data will 
enable the development of a morbid/benign variation map of the entire 22q11.2 region for testing 
with phenotypic expression.
88
Genome-wide variants that increase likelihood of expressing schizophrenia and related 
phenotypes 
Planned analyses of SNV data include logistic-regression modelling to compare allele 
frequencies between the 22q11DS schizophrenia and no psychotic illness groups, accounting for 
covariates such as sex, ethnicity, genotyping platform, and read length. Statistical significance is 
established via permutation. These sequence-based variant analyses will proceed in a logical 
fashion, using standard genome-wide approaches. These will include GWAS for common 
variants of >5% minor allele frequency (MAF), gene-based analyses for other SNPs (1-5% 
MAF), and modified Sequence Kernel Association Test (SKAT) or other burden tests for rare 
SNVs with <1% MAF.
91
 Rare coding and non-coding variants will be grouped by type (e.g., 
missense, lincRNAs) and prioritized using factors such as functional scores (e.g., CADD) and 
conservation.
15,76
 Inspection of expected variant frequencies using public databases (e.g., ExAC, 
gnomAD) will be important.
75  
Both individual variants and groups of variants at the gene or 
pathway (e.g., functional gene-set) level will be tested, using such aggregate-type tests as 
polygenic risk scores (for common variants) and burden tests (for rare variants).
15,92
 Notably, a 
test like SKAT can detect genes or pathways that contain causal variants that act in different 
directions on phenotypes (e.g., some variants may increase risk, while others decrease risk). 
Also, as noted above, there is some published evidence for the utility of functional gene-set 
based burden analyses for rare functional variants and for polygenic risk scores in 22q11DS.
15,87
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For the rapidly evolving area of analyzing non-coding variants, including intragenic enhancers 
distal to coding sequence, the most up-to-date resources and functional-based variant scoring 
methods available will be used, appropriate to common or rare variant analyses.
15,71
To test the generalizability of individual and aggregate rare and common, coding and 
non-coding, top hits will be evaluated in available general population schizophrenia samples.
85
Other resources will also be used to prioritize the schizophrenia-related variants identified in 
22q11DS, including in silico analyses of potential function (including regulatory function) using 
animal model data and human tissue expression data.
16
To adjust for multiple testing while 
avoiding overcorrection in analyses that involve inherently correlated data (e.g. testing two 
pathways that may have genetic overlap), various methods may be applied, e.g., using 
permutation or other standard methods (e.g., Benjamini-Hochberg False Discovery Rate).
15,74  
To 
appreciate the overall genomic architecture of schizophrenia in 22q11DS will require eventual 
integration of all genomic variant findings with the phenotypic data, and other downstream 
analyses to investigate potential disease mechanism and function
16
using actual animal models, 
tissue expression profiles, and spatiotemporal expression profiles during brain development
(Figure 2).
Alternative phenotype approach
Initial analyses prioritize comparisons between participants with 22q11DS and schizophrenia and 
those with no psychotic disorder over age 25 years (Table 2).
87
 Other analyses involving data 
from youths where numbers are far greater (Table 2) will test whether various definitions of 
subthreshold psychosis and related phenotypes, including IQ decline,
54
 produce similar genetic 
findings. Thus, all of the analyses described above will also be performed using alternative 
schizophrenia-related phenotypes. Notably, the vast majority of the 22q11DS sample with WGS 
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results from this cross-sectional IBBC study comprises youths with their years of greatest risk for 
psychotic illness ahead of them. 
EARLY FINDINGS
The IBBC has provided an unprecedented large sample, establishing a database for 22q11DS 
with common phenotypes that enable data integration. Initial published findings illustrate the 
promise of this consortium. In the largest study of psychiatric disorders in 22q11DS (n=1,402; 
ages 668 years) using validated diagnostic instruments, psychotic disorders were present in 
41% of adults over age 25 years. Autism spectrum disorders and ADHD in children and
adolescents, and anxiety disorders across all age ranges, were also prevalent with sex differences 
in ADHD and anxiety disorders similar to those reported in the general population.
22
To evaluate the relationship between psychosis and cognitive functioning, clinical 
assessment and IQ measures were examined longitudinally in 411 participants with 22q11DS.
54
Across the sample, mild decline in IQ, especially in the verbal domain, was noted with 
increasing age.
53
 However, in youth who developed psychotic illness, this decline was 
significantly steeper, similar to observations in schizophrenia in the general population.
94
In another recent Consortium-based paper, individuals with 22q11DS (n=692) were 
assessed for subthreshold psychotic symptoms. Nearly one-third of the participants met criteria 
for positive subthreshold psychotic symptoms and almost a quarter met criteria for 
negative/disorganized subthreshold symptoms. Adolescents (aged 1317 years) showed the
highest rates of subthreshold psychotic symptoms. Cognitive deficits were associated with 
subthreshold psychosis.
95
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To investigate the role of additional rare genome-wide CNVs in expression of 
schizophrenia in 22q11DS,
87
 high quality genome-wide CNV from the available microarrays
were annotated using stringent methods and adjudicated for rarity using independent control 
microarray data as in previous studies.
12,86,96-101
Compared to participants aged 25 years and 
older with no psychotic illness, the schizophrenia group was significantly enriched for genome-
wide rare CNVs that implicated known and novel schizophrenia risk genes and loci.
87
 Evidence 
of interactions at a network level of these genes with 22q11.2 deletion region genes is consistent 
with the threshold-lowering effect of the deletion, highlighting the importance of an integrated 
genome-wide approach.
92
A novel data mining strategy that integrates biological information from gene association, 
gene network, and disease/trait phenotypes has been developed to help prioritize potential 
schizophrenia risk genes and networks.
93
 This method is to be applied in the IBBC WGS 
analyses. Other upcoming IBBC publications include findings on novel structural 
polymorphisms that predispose to chromosome 22q11.2 rearrangements, and analysis of the 
extent to which schizophrenia polygenic risk score predicts outcome in 22q11DS. 
LIMITATIONS AND FUTURE DIRECTIONS
The IBBC has capitalized on existing global collaborations in an effort to assemble the largest 
sample available of a highly informative neurogenetic syndrome. The consortium includes 
retrospective data. While carefully assessed, the IBBC data do not have the depth and scope that 
prospective studies can attain. Importantly, prospective studies can use the same standardized 
validated and efficient measures for deep phenotyping. Such future studies could use novel tools, 
such as computerized assessment, which can be administered in multisite large scale studies 
across a broad age range, and have been validated in 22q11DS. To investigate the possible 
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contribution of environmental non-genetic factors to schizophrenia will require recontacting 
subjects or collection of new data. Prospective longitudinal studies would help address these 
limitations and enhance the contributions to the field. Although the current work of the IBBC is 
focused on schizophrenia, the dataset and findings might also be of interest to researchers 
working in other areas, such as anxiety in neurodevelopmental disorders and cognitive 
development in young people with intellectual disabilities.
The genomic efforts were also built on the expertise of established investigators and the 
promise of WGS to help delineate the genomic architecture of human disease. Nevertheless, 
other molecular approaches may well be needed to fully understand the changes wrought by a 
22q11.2 deletion, including risk for schizophrenia and the variable expression of 22q11DS in 
general. The potential roles of transcriptional regulation, post-translational modification, and 
other yet to be identified mechanisms will be important to pursue with emerging technologies. 
These investigations are likely to need expanded sample sizes. This would also be the case for 
the current study which is underpowered, despite the large sample amassed, for lower effect size 
individual variants or variant groups, and for analyses of interaction effects.
With advances in technology and reduction in costs, future studies can also consider 
informative replication samples and the best methods to address hypotheses generated in the 
field, particularly those that focus on relevant genotype-phenotype associations. Novel strategies 
to identify potential protective factors, and develop possible preventive and therapeutic 
interventions, are also promising future directions.
CONCLUSION
The IBBC has demonstrated the feasibility and utility of large-scale collaborations to examine an 
informative rare CNV that can contribute to advancing the mechanistic understanding of 
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schizophrenia spectrum disorders. The rich phenotypic dataset amassed for individuals with 
22q11DS and schizophrenia spectrum disorders, compared to those without psychotic features, 
as well as at-risk youth is unprecedented and buttresses the generalizability to schizophrenia and 
clinical risk for the disorder in the general population. Integration with the broad genomic 
approach, combining whole genome sequencing, genome-wide microarray technologies and 
novel emerging technologies can contribute to advancing the pathogenesis of schizophrenia and 
ultimately to targeted preventive and therapeutic efforts. Likely outcomes include identifying 
genetic modifiers from both the intact 22q11.2 region alleles and genome-wide
87
 that will not 
only address the key goal of delineating schizophrenia vulnerability but could also inform other 
important aspects of expression in this syndrome and beyond. The implications for other 
molecular models, for understanding development, and for neuropsychiatric research in general 
are potentially profound.
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Table 1. IBBC Sites, Roles and Samples
IBBC Site (by Group)
Samples Submitted
per Site
Toronto*^ 155
Australia 28
Santiago 73
Total by group CAN+ 256
Leuven*^ 125
Geneva 119
Maastricht 95
Marseilles 25
Tel Aviv 103
Utrecht* 151
Total by Group EUA 618
Cardiff* 122
Dublin 64
London 22
Madrid 34
Mallorca 27
Rome 89
Total by Group EUB 358
Albert Einstein NY
+
NA
CHOP-Penn*^ 335
Duke 70
Emory*^ 29
SUNY 101
UCLA 81
UC Davis 69
Total by Group USA 685
Total Samples Submitted
1
1,917
IBBC International 22q11.2 Brain Behavior Consortium
*-Indicates Group Organizing Site; ^ -Indicates both Phenomic and Genomic Site; +-Indicates Genomic 
only site; NA Not applicable 
1
Total samples submitted will be greater than the number of those with usable genomic and phenotypic 
data, after extensive data cleaning.
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Table 2. Demographic and genotypic characteristics of the 22q11DS IBBC sample with 
typical 22q11.2 deletions (c February 15, 2017)
1
Main diagnostic groups (n=582)
At risk group
(n=1,034)
Total
(n=1,616)
Psychotic 
illness
2
(n=292)
No psychotic 
illness at age ³25 y
(n=290)
n % n % n % n %
Females 143 49.0 177 61.0 513 49.6 833 51.6
Youths 
(< age 21 y)
97 33.2 - - 915 88.5 1012 62.6
European ethnicity 241 86.7 258 91.5 809 78.2 1308 80.9
A to D 22q11.2 
deletion
268 91.8 263 90.7 953 92.2 1484 91.8
WGS data 
available
271 92.8 275 94.8 918 88.8 1464 90.6
Mean SD Mean SD Mean SD Mean SD
Mean age 29.3 13.0 35.6 9.8 14.4 4.5 20.9 11.8
Age at onset 22.3 8.9 - - - - - -
1
All numbers are best estimates for subjects with typical 22q11.2 deletions, subject to data 
checking and cleaning; individuals (total n=301 of 1,917) without available 22q11.2 deletion 
data as yet, and a small number (<20) with atypical 22q11.2 deletions, are not included (see text 
for details).
2
The psychotic illness designation comprises schizophrenia (66.1%), schizoaffective or psychotic 
disorder not otherwise specified (25.3%), or other psychotic spectrum disorders (8.6%), but 
excludes a small number of subjects with psychotic mood disorders.
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Figure legends
Figure 1. The 22q11.2 region. Cytogenetic representation of chromosome 22 showing the short 
(p) and long (q) arms with the centromere, which functions to separate both arms. Chromosome 
22 is an acrocentric chromosome, as indicated by the two horizontal lines in the p arm.  The 
22q11.2 deletion occurs on the long arm of one of the two chromosomes, depicted by dashed 
lines in the 22q11.2 band. The position of the two low copy repeats (LCRs) on 22q11.2 
(LCR22A and LCR22D), which flank the typical 3-Mb deletion, LCR22B and LCR22C and 
genes (protein-coding and selected non-protein-coding) within the 22q11.2 deletion region, as 
well as the three typical 22q11.2 deletions that include LCR22A and two nested 22q11.2 
deletions that do not include LCR22A (all indicated by blue bars below), are depicted in the 
inset.
13
Figure 2. Genomics flow diagram.
The figure provides an overview of the ongoing and planned genomics analyses in the IBBC 
study, beginning with genomic DNA samples available from subjects with 22q11DS from 
participating international centers. Samples were sent to one laboratory (Albert Einstein College 
of Medicine, NY) that serves as a central clearinghouse, and provides a unique IBBC 
identification number to enable linking of genotypic and phenotypic data. Data primarily from 
studies that pre-dated the IBBC are indicated on a cyan background. The mauve and yellow 
backgrounds indicate data generated from the IBBC study from WGS and microarray data, 
respectively. Dotted lines indicate the work flow for microarray data. These provided data for 
initial analyses, and available for comparison with WGS data, albeit at lower resolution. Red font 
indicates analyses using the phenotypic data available for subjects with 22q11DS from 
participating international centers. Main analyses involve comparisons of subjects with 22q11DS 
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and schizophrenia vs. those with no psychotic illness at age 25 years and older. See text for 
details. 
1
Quality control measures applied to both WGS and microarray data include checking for 
duplicate and related samples, for sex and ethnicity using phenotypic data to help detect sample 
mix-ups, and for 22q11.2 deletion size (assisted by available multiplex ligation dependent probe 
amplification (MLPA) data and heat-map data generated from microarrays). Additional quality 
control measures, following transfer of raw WGS data (fastq files) generated at HudsonAlpha 
Genome Sequencing Center (Huntsville, AL) to the Human Genetics Computational Cluster 
(Emory U), include checking for mixing of samples, level of genetic variation, base transition to 
transversion ratios, too many variants in particular regions, and variants that departed from 
HardyWeinberg equilibrium at p<10
-4
. 
2
The intact haploid 22q11.2 allele requires special computational considerations, thus is analyzed 
separately from data from the rest of the genome.
82,83
3
Annotation of structural variation from WGS data is a pioneering area of genomics. Availability 
of CNV data from standard microarrays in this study will be valuable for comparison 
purposes.
74-77
4
Integrated analysis using all variant data, common and rare, sequence and structural, will 
provide an overview of the genomic architecture of schizophrenia in 22q11DS. Validation 
studies, e.g., polymerase chain reaction for SNV, quantitative polymerase chain reaction for SV, 
will proceed according to results.
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CNV = copy number variation; LOF = loss of function; SNP = single nucleotide polymorphisms 
(common sequence variants); SNVs = single nucleotide variants; SV = structural variants; WGS 
= whole genome sequencing
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McDonald-McGinn, D. M. et al. (2015) 22q11.2 deletion syndrome
Nat. Rev. Dis. Primers doi:10.1038/nrdp.2015.71
Figure 1 - Chromosome 22 ideogram with inset indicating low copy repeats and genes within the 22q11.2 region 
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